uploads///Chart  Keytruda

Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug

By

Jan. 19 2018, Updated 7:34 a.m. ET

Keytruda

Merck & Co.’s (MRK) immuno-oncology portfolio includes one of its key products—Keytruda—which was launched in 2014 and is approved for various indications that we’ll list below.

The above chart compares Keytruda’s sales over the last 11 quarters.

Article continues below advertisement

Keytruda’s revenues

Keytruda sales increased 194% to ~$1.1 billion in 3Q17 compared to $356 million in 3Q16, driven by an increase of ~192% in revenues at constant exchange rates and a 2% favorable impact of foreign exchange.

Keytruda’s uses

Keytruda is approved for the treatment of various forms of tumors for the following diseases:

  • head and neck squamous cell cancer
  • classical Hodgkin lymphoma
  • microsatellite instability-high cancer
  • advanced non-small cell lung cancer (or NSCLC)
  • advanced melanoma
  • advanced urothelial bladder cancer

Keytruda is also approved for patients with PD-L1 positive gastroesophageal junction adenocarcinoma, a type of stomach cancer.

Article continues below advertisement

Recent developments for Keytruda

Keytruda is a drug being evaluated for more than 30 tumor types as a monotherapy as well as a combination drug.

On January 16, 2018, Merck announced data from its KEYNOTE-189 study, a double-blind, randomized, Phase 3 study evaluating Keytruda in combination with other drugs, including pemetrexed, and cisplatin or carboplatin, as first-line treatments for metastatic NSCLC. It met its primary endpoints of overall survival as well as progression-free survival.

On January 8, 2018, Merck and the European Organisation for Research and Treatment of Cancer announced data from its EORTC1325/KEYNOTE-054 study, a Phase 3 study evaluating Keytruda as a monotherapy for the treatment of surgically resected high-risk melanoma. It met its primary endpoint of recurrence-free survival.

The Health Care Select Sector SPDR ETF (XLV) holds 4.8% of its total investments in Merck (MRK), 3.1% in Bristol-Myers Squibb (BMY), 3.1% in Gilead Sciences (GILD), and 6.6% in Pfizer (PFE).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.